BRIEF-Unprecedented Results From The Phase 3 MajesTEC-3 Study Support TECVAYLI Plus DARZALEX FASPRO As A Potential Standard Of Care As Early As Second Line For Patients With Relapsed/Refractory Multiple MyelomaDec 9 (Reuters) - Johnson & Johnson JNJ.N:
UNPRECEDENTED RESULTS FROM THE PHASE 3 MAJESTEC-3 STUDY SUPPORT TECVAYLI® PLUS DARZALEX FASPRO® AS A POTENTIAL STANDARD OF CARE AS EARLY AS SECOND LINE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
J&J - TECVAYLI AND DARZALEX SHOW SIGNIFICANT SURVIVAL ADVANTAGE
J&J - SUBMITS SBLA FOR TECVAYLI AND DARZALEX COMBINATION AS TREATMENT FOR RRMM
Source text: ID:nPn84198Ca
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments